A single-arm interventional clinical study evaluating sintilimab in combination with ipilimumab as adjuvant therapy in patients with resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) who have undergone surgery but did not achieve pathological complete response (pCR) after neoadjuvant treatment with sintilimab combined with platinum-based doublet chemotherapy (ChiCTR) - Oct 16, 2026 - P4 | N=56 | Not yet recruiting | Sponsor: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
New P4 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|